This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
WestRock Company announced the filing of the initial Form 10 registration statement for Ingevity Corporation with the U.S. Securities and Exchange Commission ("SEC"). Ingevity, the specialty chemicals business of WestRock, will become a new independent public company following the successful completion of its separation from WestRock. Ingevity is expected to trade on the New York Stock Exchange under the symbol of "NGVT." Upon completion of the spinoff of Ingevity, which is expected to occur in the first calendar quarter of 2016, WestRock shareholders as of the record date for the separation will own 100 percent of the new company.
"Today's filing continues the progress we are making to separate the specialty chemicals business from WestRock," said Steve Voorhees, chief executive officer, WestRock Company. "The separation of Ingevity from WestRock will better position both businesses to pursue their respective operating priorities and strategies, and to focus on their unique opportunities for long-term growth and profitability."
"I am extremely proud of the tremendous effort the Ingevity team has made to prepare for the separation, while also remaining focused on operating safely, meeting customers' expectations and delivering on our financial commitments," said Michael Wilson, the chief executive officer of Ingevity. "As a result, we believe we are well positioned to become a successful independent public company."
